| abstract |
The present invention features a solid pharmaceutical composition comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition comprises (1) a first layer comprising 100 mg of Compound 1, and a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated into an amorphous solid dispersion; and (2) a second layer comprising 40 mg of Compound 2, and a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all formulated as an amorphous solid dispersion. |